Prostate post-implant dosimetry: interobserver variability in seed localisation, contouring and fusion.

AIM Reliable post-implant evaluation of prostate seed implants requires optimal seed identification and accurate delineation of anatomical structures. In this study the GEC-ESTRO groups BRAPHYQS and PROBATE investigated the interobserver variability in post-implant prostate contouring, seed reconstruction and image fusion and its impact on the dose-volume parameters. MATERIALS Post-implant T2-TSE, T1-GE and CT images were acquired for three patients, in order to evaluate four post-plan techniques: (a) CT, (b) T1+T2, (c) CT+T2, (d) CT+T1(int)+T2. Three interobserver studies were set up. (1) Contouring: the CTV-prostate was delineated on CT and T2 by eight physicians. Additionally one reference contour was defined on both image modalities for each patient. (2) Seed reconstruction: seven physicists localised the seeds on T1 and CT, manually and with CT seed finder tools. A reference seed geometry was defined on CT and T1. (3) Fusion: six physicists registered the image sets for technique (b)-(d), using seeds (if visible) and anatomical landmarks. A reference fusion was determined for each combined technique. RESULTS (1) The SD(ref) for contouring (1 SD with respect to the reference volume) was largest for CT (23%), but also surprisingly large for MRI (17%). This resulted in large SD(ref) values for D90 for all techniques (17-23%). The surprisingly large SD(ref) for MRI was partly due to variations in interpretation of what to include in the prostate contour. (2) The SD(ref) in D90 for seed reconstruction was small (2%) for all techniques, except for T1+T2 (7%). (3) The SD(ref) in D90 due to image fusion was quite large, especially for direct fusion of CT+T2 (16%) where clearly corresponding landmarks were missing (seeds hardly visible on T2). In general, we observed large differences in D90 depending on the technique used. CONCLUSIONS The dosimetric parameters for prostate post-implant evaluation showed large technique-dependent interobserver variabilities. Contouring and image fusion are the 'weak links' in the procedure. Guidelines and training in contouring together with incorporation of automated fusion software need to be implemented.

[1]  Ivan Yeung,et al.  MRI-CT fusion to assess postbrachytherapy prostate volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy. , 2004, Brachytherapy.

[2]  E Bellon,et al.  The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[3]  J J Prete,et al.  Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. , 1998, Radiology.

[4]  C. Giberti,et al.  Dosimetry doesn't seem to predict the control of organ-confined prostate cancer after I-125 brachytherapy. Evaluation in 150 patients. , 2009, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[5]  P. Mangili,et al.  Comparative study of permanent interstitial prostate brachytherapy post-implant evaluation among seven Italian institutes. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  P. Grimm,et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[7]  Dan Ash,et al.  Impact of prostate volume evaluation by different observers on CT-based post-implant dosimetry. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  L. Potters,et al.  A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. , 2001, International journal of radiation oncology, biology, physics.

[9]  K. Wallner,et al.  Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. , 2007, International journal of radiation oncology, biology, physics.

[10]  D. Ash,et al.  ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Wendy L. Smith,et al.  Prostate volume contouring: a 3D analysis of segmentation using 3DTRUS, CT, and MR. , 2007, International journal of radiation oncology, biology, physics.

[12]  Patrick W McLaughlin,et al.  The use of mutual information in registration of CT and MRI datasets post permanent implant. , 2004, Brachytherapy.

[13]  D. Ash,et al.  Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  D. Engeler,et al.  Topological methods for the comparison of structures using LDR-brachytherapy of the prostate as an example , 2009, Physics in medicine and biology.

[15]  Dan Ash,et al.  The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  W. Lee Permanent prostate brachytherapy: the significance of postimplant dosimetry. , 2004, Reviews in urology.

[17]  Christian Kirisits,et al.  Accuracy of seed reconstruction in prostate postplanning studied with a CT- and MRI-compatible phantom. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .

[19]  A. Agranovich,et al.  Computed tomography determination of prostate volume and maximum dimensions: a study of interobserver variability. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  Phantom investigations on CT seed imaging for interstitial brachytherapy. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[22]  J J Prete,et al.  Comparison of MRI- and CT-based post-implant dosimetric analysis of transperineal interstitial permanent prostate brachytherapy. , 1998, Radiation oncology investigations.

[23]  Roberto Orecchia,et al.  MR and CT image fusion for postimplant analysis in permanent prostate seed implants. , 2004, International journal of radiation oncology, biology, physics.

[24]  Alex Rijnders,et al.  Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  M van Herk,et al.  Definition of the prostate in CT and MRI: a multi-observer study. , 1999, International journal of radiation oncology, biology, physics.

[26]  Wayne M Butler,et al.  Evaluation of radiobiologic biochemical control in a large permanent prostate brachytherapy population from a single institution using AAPM TG-137 parameters. , 2011, Brachytherapy.

[27]  M. Middleton,et al.  Prostate contouring variation: can it be fixed? , 2012, International journal of radiation oncology, biology, physics.